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Abstract 
 
Economic models are being increasingly used by health economists to assess the value of health 
technologies and inform healthcare decision-making. However, most published economic models 
represent a kind of black box, with known inputs and outputs but undisclosed internal calculations and 
assumptions. This lack of transparency makes the evaluation of the model results challenging, 
complicates comparisons between models, and limits the reproducibility of the models. Here, we aim to 
provide an overview of the possible steps that could be undertaken to make economic models more 
transparent and encourage model developers to share more detailed calculations and assumptions with 
their peers. Scenarios with different levels of transparency (i.e. how much information is disclosed) and 
reach of transparency (i.e. who has access to the disclosed information) are discussed and five key 
concerns (copyrights, model misuse, confidential data, software, and time/resources) pertaining to model 
transparency are presented along with possible solutions. While a shift toward open-source models is 
underway in health economics, as it happened before in other research fields, the challenges ahead should 
not be underestimated. Importantly, there is a pressing need to find an acceptable tradeoff between the 
added value of model transparency and the time and resources needed to achieve such transparency. To 
this end, it will be crucial to set incentives at different stakeholder levels. Despite the many challenges, 
the many benefits of publicly sharing economic models make increased transparency a goal worth 
pursuing. 
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KEY POINTS 
 Health economics models are often challenging to understand, interpret, and reproduce as they 
lack or report limited information regarding underlying calculations and assumptions 
 
 
 We provide an overview of the ongoing debate on economic model transparency as well as 
discuss the key challenges facing the implementation of fully transparent models along with 
possible options and solutions 
 
 A concerted effort involving the research community, modelers, academics, and scholarly 
journals is needed to improve the level of transparency (i.e. how much information is disclosed) 
and reach of transparency (i.e. who has access to the disclosed information) of economic models 
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1. Introduction  
Economic models are being increasingly used in conjunction with efficacy and safety data to assess the 
value of health technologies [1, 2]. However, published economic models generally lack transparency, 
with transparency broadly defined as full accessibility to any information related to how the model was 
built, and thus full reproducibility [3]. Indeed, economic models are typically described in terms of key 
assumptions, inputs, data sources, and outputs but the internal components and assumptions are often not 
detailed enough to allow other researchers to reproduce the model or fully interpret the results [1, 4]. In 
particular, the underlying code or calculations are rarely, if ever, shared. As a result, economic models 
represent a kind of black box with known inputs and outputs but undisclosed internal structure and 
calculations. To assess the robustness and validity of a model, sensitivity analyses are typically conducted 
to evaluate whether, and to which extent, alternative assumptions may alter the model results. 
Nonetheless, sensitivity analyses do not completely solve the issue of limited transparency as authors may 
consider only the most convenient scenarios [4].  
The lack of detailed descriptions of internal model structures and equations complicates comparisons and 
makes the evaluation of the model results challenging [4, 5]. More transparency would assuage concerns 
that payers and other stakeholders have expressed regarding the reliability of economic models as well as 
allay the perception that commercially sponsored models are inherently biased [5]. Making a more 
detailed description of all the steps used to build an economic model publicly available would allow 
researchers to more easily validate the model results, compare the model with other available models, 
update the model inputs based on the most recent evidence, adapt the model to local health systems or 
different therapeutic areas, and reduce duplication of efforts [6].   
To further the discussion on model transparency and how to achieve it, we aim to provide an overview of 
the ongoing debate on model transparency as well as discuss the key challenges facing the 
implementation of fully transparent models along with possible options and solutions. The paper is 
structured as follows: Section 2 presents the different options for model transparency; Section 3 presents 
the key issues with model transparency and Section 4 presents the potential solutions.  
 
2. Options for model transparency  
While there is a general consensus that the way economic models are reported should be improved, how 
to achieve this goal is the subject of intense debate. In particular, the pros and cons of making published 
economic models openly available to researchers and healthcare stakeholders are being increasingly 
discussed in the literature [2, 4-7]. Generally speaking, possible scenarios for model transparency rests on 
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finding an appropriate solution to two main issues (Figure 1): level of transparency (i.e. how much 
information is disclosed) and reach of transparency (i.e. who has access to the disclosed information). The 
current level of transparency of published economic models can be considered low as the model internal 
structure and computations are not fully disclosed, most often neither to the journal nor to the readers. To 
increase the level of transparency, a graphical user interface (GUI) could be set up with a full list of 
model assumptions; data inputs and model settings so that users can interact with the model by selecting 
the inputs that are of interest to them and visualizing the outputs [16]. A GUI-based solution that allows 
users to perform additional analyses other than the ones reported in the original publication would further 
the users’ understanding of the model structure and computations [16]. Given that, in this case, the code 
or internal calculations would not be visible, this would be considered a medium level of transparency. 
Full transparency would be achieved only by releasing every single step and process involved in building 
the model, including the source code.  
One of the most touted solutions to the problem of model transparency is that of open source models, 
suggested by health economists [2, 4, 6, 17] and the ISPOR-SMDM Modeling Good Research Practices 
Task Force [18, 19]. In the open-source framework, detailed descriptions of the model inputs, outputs, 
structure, and outcomes are made available to the public along with all the codes and calculations used to 
build the model, either in a repository or upon request [2]. In particular, releasing the source code is 
believed by many to be the best possible way to ensure that the model is reproducible and its assumptions 
valid [6, 20]. Some modelers have already chosen the full open-source route and have made their source 
code, developed either in R or Excel, downloadable. Examples include the model developed by Sullivan 
et al. [20] in pain therapy, the IVI Rheumatoid Arthritis (IVI RA) model [12], the IVI NSCLC model in 
non-small cell lung cancer[13], and the models found in the Global Health Cost Effectiveness Analysis 
(GHCEA) registry [14] and in the University of Exeter’s repository [15]. However, it should be noted 
that these examples represent the exception rather than the norm. 
Besides the level of transparency, the issue of who has access to the model information should also be 
addressed. Indeed, the modeler could share the full model only with the party that commissioned the 
model such as funding agency or company (low reach of transparency), only with the health technology 
assessment (HTA) agencies (e.g. NICE) to whom the model is submitted and/or any other relevant 
stakeholders such as academic groups (medium reach of transparency), or with the public at large, either 
depositing the model in a repository or making it available upon request (high reach of transparency).  
The scenarios with a high level and reach of transparency (Figure 1), commonly associated with open 
source models, carry some risks that may result in unintended consequences. The potential issues and 
drawbacks associated with increased model transparency need to be carefully evaluated before making 
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any determinations. To this end, five main concerns (copyrights, model misuse, confidential data, 
software, and time/resources) pertaining to model transparency are discussed below, along with possible 
solutions.  
 
3. Issues with model transparency  
Currently, when a model-based manuscript is published in a journal, the authors transfer to the journal the 
copyrights of the content of the manuscript but not those of the source code, which can therefore be 
reused by the authors at will. Whether, and the extent to which, the source code should be released is 
currently a sticking point in the ongoing debate on model transparency. Some researchers like Padula et 
al. [5, 7] have argued that publication of the source code would compromise the copyrights of the 
modelers and, as a result, would discourage the creation of economic models. This could be true 
especially for complex models. Others like Cohen at al. [4] have argued that publication of the full source 
code would not affect the ‘intellectual value’ of the model as the most valuable part of the model rests on 
the internal assumptions — which, theoretically, should already be reported in the methods section of a 
manuscript — not on the lines of code, which are simply used to implement the model assumptions. The 
scientific credibility of a model, they reckon, depends on its reproducibility, which in turn depends on the 
availability of the source code. How to reconcile these opposing views and create sharing standards that 
take into account a modeler’s copyrights?  
Besides copyrights, once the underlying lines of code are made publicly available, a system that 
guarantees that each published model is appropriately cited when fully or partially used to build a new 
model should be in place. How can such a system be built? 
Another concern regarding open-source models is that people not trained in, or with limited knowledge 
of, economic models may use an openly available model and generate misleading results regarding the 
value of different treatment options [5]. Given the potential harm to patients, this issue should not be 
dismissed and safeguards should be put into place to minimize the risk of improper or unethical use of 
open-source models. Cohen et al. [4] argued that making models open source would protect against 
misuse in itself as researchers would eventually uncover any improper use or alteration of a model and 
report it. However, it should also be noted that economic models are often complex, depending on the 
therapeutic area, data availability, or treatment regimens. The more complex the model, the easier it is to 
misuse or misinterpret it as only a few parties have the skills, experience, and resources to fully 
understand and critically review it [4, 6]. What measures should be implemented to avoid model misuse 
and dissemination of misleading results?  
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The use of confidential information that is often needed to build an economic model (e.g. individual 
patient data) should also be weighted when considering the open-source path. Journals have specific 
guidelines and requirements in place for when confidential data are used in a publication, whether model-
based or not. Precautions should be taken when publicly sharing economic models as well. How to 
reconcile the use of confidential information with the need for more transparency? 
Another important issue that needs to be addressed when discussing open-source models is that of 
proprietary software. To be usable, open-source models require software that is freely or widely available 
and easy to share. Currently, most economic models are developed in Excel (e.g. Snowsill et al. [15]), 
which is part of Microsoft Office, or R (e.g. Sullivan et al. [20] and IVI RA Model ), which is freely 
available, but proprietary software (such as TreeAge, Simul8, and Arena) could also be used. Some 
vendors make the source code available to customers, who can then modify it but, typically, cannot 
redistribute it. How to reconcile the use of proprietary software with the need for more publicly available 
and accessible models?  
The time and resources needed to make models more transparent and accessible should not be 
overlooked, particularly because most of the onus will rest with the researchers creating the models. 
Copies will need to be created and uploaded to repositories or shared with other researchers upon request. 
In some cases, GUIs will need to be created as well, as mentioned above. Countermeasures to avoid 
accidentally disclosing confidential information may also need to be implemented. Training modelers on 
what constitutes confidential, and thus not disclosable, information may be a first step in the right 
direction. Built-in countermeasures embedded in the code itself may be another option. Furthermore, 
since an open model should be readily available but also easily interpretable, modelers may need to spend 
time adding comments and annotations, based on common standards or repositories’ policies, that they 
may otherwise not include in the code. Technical support for researchers using models made publicly 
available may also be required to clarify a model’s structure or assumptions on an ongoing basis. Given 
the amount of work required to make models publicly available, how to motivate researchers to share 
their models? 
 
4. Possible solutions 
To mitigate the problem of possible infringement of a modeler’s copyrights when publicly disclosing the 
source code, several measures have been proposed. One option would be to request that anybody 
(whether an individual researcher or a pharmaceutical company) wanting to reuse the model to ask for 
permission and/or pay a licensing fee [5]. When publishing the results of a study that used a model 
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developed by other researchers, the model creators should be acknowledged and proof of permission to 
publish or payment of the licensing fee should be provided to the journal. To facilitate the sharing of the 
models, including the source code, without compromising the copyrights of the modelers, a central 
repository, or several repositories based on the type of economic model, could be created. As proposed by 
Padula et al. [5], the use of unique digital IDs associated with the models deposited in a repository would 
ensure that modelers, or the repository itself, can track who has downloaded their model(s) and make sure 
that the terms of use are respected and the licensing fee paid. Assigning digital IDs to individual 
economic models could lay out the basis for a citation system similar to the DOI (Digital Object 
Identifier) system currently used for published articles, further motivating researchers to share their 
models as they would become part of their publication list and academic curriculum. Such system may 
also motivate academic institutions to relax their copyright and licensing policies, which tend to be very 
strict, given the potential to further their reputation by increasing the number of citations attributed to 
their researchers. As suggested by Bierer et al. [21], recognition of data authorship (in this case, 
recognition of model authorship) via digital IDs may act as an incentive for data/model sharing and foster 
collaborations among researchers, further advancing the field of health economics. The growing use of 
repositories in other research fields suggests that this solution is not farfetched. For instance, cognitive 
neuroscientists have long shared their computational models in repositories like ModelDB [22], which 
contains over 1000 public models [23]. GitHub [24] is another popular repository across research areas, 
where users can choose whether to retain or forego their copyrights. Nevertheless, it should be noted that 
copyrights laws vary across countries, adding an extra layer of complexity to the problem [25]. For 
instance, Creative Commons licenses – which enable the free distribution of a copyrighted work without 
requiring authors to relinquish their copyrights – are not uniformly recognized worldwide and enforcing 
them has been problematic thus far [26]. 
In addition to repositories, sharing standards and regulations could be mandated by funding agencies. 
Currently, the National Institutes of Health (NIH) and the National Science Foundation (NSF) have 
specific model sharing requirements and mandates for certain types of grants and funding initiatives [22]; 
other agencies could follow their example. Journals would play a key role in mandating the use of 
repositories. Some journals (e.g. Plos ONE, Science, and the Journal of Biological Chemistry) already 
require models be shared when they are a key to obtaining the published results, but the vast majority of 
journals only encourage this practice. In the clinical realm, ClinicalTrials.gov [27] is a good example of 
how mandating the registration of privately or publicly funded trials as condition for publication in peer-
reviewed journals can increase the popularity of a database. Recognizing the issue of copyrights 
infringement when making a model fully open source, the ISPOR-SMDM joint task force suggested 
making all the technical details of a model, including the source code, available to peer reviewers after a 
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study is submitted for possible publication to a journal given that reviewers are bound to confidentiality 
[18]. A similar proposal has been advanced by the International Committee of Medical Journal Editors 
[28]. However, many journals may not be well equipped to take on the task of mandating full disclosure 
of the source code and some restructuring within the publishing industry may need to take place for that 
to happen. One issue that will need to be addressed, for instance, is that peer reviewers may not be 
inclined to spend time and effort reviewing a model’s calculations or lines of code unless appropriately 
motivated, monetarily or otherwise.  
To minimize the risk of model misuse, more training in health economics and economic modeling may be 
required for all healthcare stakeholders, including researchers and payers. To curtail the dissemination of 
deceitful or inaccurate results more health economics training among health care professionals may also 
be needed. Padula et al. [5, 7] advocated for a curriculum reform for medical students given that they 
represent some of the future healthcare professionals that could benefit the most from a better 
understanding of economic models. We agree that introducing medical students to the basic concepts of 
economic modeling, particularly cost-effectiveness analysis, would help translate model results into 
practice and prevent the spread of misinformation based on the improper use of openly available models. 
However, we recognize that the medical school curriculum is already burdensome and adding extra 
courses or modules may be challenging. It would be important for health economists to work with the 
American Association of Medical Colleges (AAMC) to find possible avenues of collaboration and 
identify possible training opportunities during or after medical school, as also proposed elsewhere [5]. In 
addition to training healthcare professionals on the principles of health economics, safeguards should be 
embedded in the dissemination of open models through repositories, journals, or funding and HTA 
agencies, as mentioned above. The reference models proposed by Afzali and Karnon [29] may also 
contribute to reducing model manipulation and misuse by standardizing models by therapeutic area.   
Besides model misuse, accidental disclosure of the confidential data that often populate an economic 
model is a major concern for which a solution that does not compromise the reliability of the model itself 
is needed. One option would be to use dummy data so that other researchers can reuse the model without 
having access to the original dataset. Another option would be to add a random error to the confidential 
data; however, the error may mask a feature of interest. Synthetic, but statistically identical, data could 
also be used as done for the Synthetic Longitudinal Business Database (SynLBD) based on US census 
data [30]. Depending on the type of data, standards should be established to safeguard the confidentiality 
of the data researchers use in their models.  
Regarding the issue of proprietary software, when submitting a model to a journal or an HTA agency, a 
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possible solution would be to engage only reviewers with knowledge of that particular software, though 
this may slow down the review process as fewer reviewers may be available. Some commercial software 
(e.g. TreeAge) allows users to convert models to Excel, facilitating model review. Models created with 
proprietary software are not necessarily flawed or inaccurate, therefore researchers should not be 
penalized for using it. A delicate balance based on a modeler’s available resources and modeling needs 
should be struck between the right of modelers to use proprietary software and the necessity of more 
transparency in the field of health economics.  
As all the issues discussed above indicate, making a model transparent and accessible to other researchers 
is a task that requires time and effort. As such, researchers making their models publicly available should 
be acknowledged and properly credited for providing a useful service to the whole health economics 
community. However, incentives are needed to improve the transparency and sharing of economic 
models. Compensating modelers for their time and effort in making models more transparent, for instance 
in the form of licensing fees, could be a powerful financial incentive. In addition, regulatory and 
reimbursement agencies could be crucial in providing incentives and motivating researchers to contribute 
to model transparency. Currently, most HTA agencies (e.g. NICE, CADTH, PBAC) require the model in 
full, including the source code. Sometimes agencies review the whole model or build their own scenario 
tests. For example, NICE typically delegates the assessment of a model (and the source code) submitted 
by a pharmaceutical company to an independent evidence review group. At the end of the review process, 
only a report, not the full model, is shared with the public. Should a few HTA agencies start to require the 
full model be made public after appraisal, other may follow and the practice may easily expand to models 
published in peer review journals. However, this change would require substantial modifications to the 
overall HTA review process and may receive pushback from pharmaceutical companies and other 
healthcare stakeholders, particularly if the concerns discussed above are not adequately addressed.  
 
5. Conclusions 
A shift toward open-source models is underway in health economics, as it happened before in other 
research fields such as genomics, protein structure, and cognitive neuroscience. Nonetheless, several key 
issues still need to be addressed and the challenges ahead should not be underestimated. An important 
first step would be to find a reasonable solution to the issue of possible infringement of a modeler’s 
copyrights. The potential misuse of publicly shared models and the use of confidential information and 
proprietary software should also be weighted. Whenever possible, model complexity should be reduced to 
facilitate the interpretation and dissemination of model results, making sure that a model is as simple as it 
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can be while representing the disease or phenomenon of interest appropriately – but without redundant 
complexity. Importantly, there is a pressing need to find an acceptable tradeoff between the added value 
of model transparency and the time and resources needed to achieve such transparency. Last but not least, 
besides implementing sharing standards and policies, it will be critical to induce a cultural shift in the 
health economics community. Despite the challenges, the many benefits of publicly sharing economic 
models make increased transparency a goal worth pursuing.  
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FIGURES 
 
Fig. 1 Level and reach of transparency: possible scenarios 
 
HTA: Health Technology Assessment; GUI: Graphic User Interface 
